The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes.
Faster Aspart
glycemic index
meal test
type 1 diabetes
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
12 Aug 2022
12 Aug 2022
Historique:
received:
22
07
2022
revised:
06
08
2022
accepted:
10
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Despite multiple pharmacological options, including rapid-acting insulin analogs, postprandial hyperglycemia is still highly prevalent in patients with type 1 and type 2 diabetes. We hypothesize that the new rapid-acting insulin formulation, the so-called faster-acting Aspart, may have a different effect in controlling postprandial hyperglycemic burden according to the quality of the meal compared to the traditional Aspart. Twenty-five patients with type 1 diabetes were consecutively recruited at the diabetes care center of the University Hospital affiliate of the Magna Græcia University of Catanzaro. Each patient performed four meal tests one week apart, two with a predefined high glycemic index (HGI) food and two with a low glycemic index (LGI) food using insulin Aspart once and Faster Aspart the other time. The 0-30 min, 0-60 min, and 0-120 min glucose Area Under the Curve (AUC) of postprandial glycemic excursion, calculated from continuous glucose monitoring data, were significantly lower with Faster Aspart administered before the HGI test meal as compared to Aspart. A significant difference in favor of Faster Aspart was also found when comparing the 0-60 min and 0-120 min AUC after the LGI meal. Faster Aspart may provide better postprandial glucose control than Aspart regardless of the glycemic index of the meal.
Identifiants
pubmed: 36014822
pii: nu14163316
doi: 10.3390/nu14163316
pmc: PMC9414780
pii:
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Insulin Aspart
D933668QVX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
CI has provided advisory board services and received speaker fee from Novo Nordisk; AC has received research grant from Novo Nordisk. Other authors do not have conflicts of interest.
Références
Intern Med. 2015;54(16):1961-9
pubmed: 26278285
Eur J Endocrinol. 2014 Mar 08;170(4):539-45
pubmed: 24412929
Diabetes Obes Metab. 2019 Apr;21(4):961-967
pubmed: 30537180
Pharmacol Rev. 2000 Mar;52(1):1-9
pubmed: 10699152
Diabetes Technol Ther. 2018 Jun;20(6):395-402
pubmed: 29901421
Diabet Med. 2020 Apr;37(4):522-531
pubmed: 30585663
Nutrients. 2019 Jul 10;11(7):
pubmed: 31295897
Clin Pharmacokinet. 2017 May;56(5):551-559
pubmed: 28205039
Diabetes Care. 2013 Dec;36(12):3897-902
pubmed: 24170749
Front Cell Infect Microbiol. 2020 Dec 09;10:575559
pubmed: 33363049
Diabetes Technol Ther. 2018 Jun;20(6):428-433
pubmed: 29923775
Diabetes Care. 2017 Jul;40(7):951-957
pubmed: 28483786
Diabetes Care. 2011 Oct;34(10):2237-43
pubmed: 21949221
Neurology. 2006 Jul 25;67(2):235-40
pubmed: 16864814
J Diabetes. 2022 Jul;14(7):485-487
pubmed: 35842915
Diabetes Obes Metab. 2018 Dec;20(12):2885-2893
pubmed: 30259644
Diabetes Obes Metab. 2015 Jul;17(7):682-8
pubmed: 25846340
Cell Metab. 2021 Mar 2;33(3):479-498
pubmed: 33529600
Am J Med Sci. 2012 Aug;344(2):136-41
pubmed: 22270400
JAMA. 2000 May 17;283(19):2552-8
pubmed: 10815119
Clin Pharmacokinet. 2020 Feb;59(2):155-172
pubmed: 31667789
Nutr Metab (Lond). 2019 Jul 17;16:46
pubmed: 31346341
Am J Clin Nutr. 2006 Nov;84(5):1171-6
pubmed: 17093171
Arch Intern Med. 2001 Feb 12;161(3):397-405
pubmed: 11176766
Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84
pubmed: 33298417
Diabetes Care. 2017 Jul;40(7):943-950
pubmed: 28356319
Diabet Med. 2021 Mar;38(3):e14515
pubmed: 33420727
J Clin Endocrinol Metab. 2008 Apr;93(4):1345-50
pubmed: 18198229
Diabetes Ther. 2016 Jun;7(2):335-48
pubmed: 27233285
Diabetes Res Clin Pract. 2011 Jul;93(1):31-7
pubmed: 21497935
Diabetes Care. 2020 Aug;43(8):1710-1716
pubmed: 32209647
Diabetes Obes Metab. 2012 Sep;14(9):780-8
pubmed: 22321739
Diabetes Res Clin Pract. 2014 Feb;103(2):256-68
pubmed: 23481145
Endocr Rev. 2001 Oct;22(5):706-17
pubmed: 11588149
Pediatr Diabetes. 2017 Dec;18(8):903-910
pubmed: 28165180
Diabetes Care. 2019 Jul;42(7):1255-1262
pubmed: 31076415
Diabet Med. 1996 Jul;13(7):625-9
pubmed: 8840095
Diabetes Obes Metab. 2018 May;20(5):1148-1155
pubmed: 29316130
J Natl Cancer Inst. 2002 Sep 4;94(17):1293-300
pubmed: 12208894
Diabetes Care. 2005 Nov;28(11):2626-32
pubmed: 16249530